WATERTOWN, Massachusetts, April 9, 2026
Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader, marking a major milestone in the advancement of targeted protein degradation (TPD) therapies for oncology. The agreement triggers a $45 million milestone payment to Kymera and positions Gilead to lead the next phase of development, including IND-enabling studies aimed at a 2027 regulatory filing. This collaboration underscores the growing importance of precision medicine approaches in addressing complex cancers and reflects strong industry momentum toward innovative drug discovery platforms.
Advancing Precision Oncology Through Targeted Protein Degradation
The investigational candidate KT-200 represents a novel therapeutic strategy designed to selectively degrade CDK2, a critical protein involved in tumor cell proliferation, rather than merely inhibiting its activity. This approach offers significant advantages over traditional therapies, as CDK2 inhibitors often lack specificity and can affect related proteins, leading to unwanted side effects.
By targeting CDK2 in CCNE1-amplified cancers, including aggressive breast and solid tumors, KT-200 demonstrates the potential to provide more precise, effective, and safer treatment options. Preclinical studies have shown low-nanomolar degradation potency, strong anti-tumor activity in cell and animal models, brain penetration capability, and a favorable safety profile, highlighting its promise as a next-generation oncology therapy.
Strategic Collaboration and Development Pathway
Advertisement
Under the terms of the agreement, Gilead Sciences will assume responsibility for global development, manufacturing, and commercialization, while Kymera remains eligible for up to $750 million in total milestone payments, along with tiered royalties on future product sales.
To date, Kymera has already received $85 million in upfront and option-related payments, reflecting the value of its innovative discovery engine and pipeline capabilities. The transition of KT-200 into IND-enabling studies marks a critical step in the drug development lifecycle, moving the candidate closer to clinical evaluation and potential regulatory approval.
Transforming Cancer Treatment with Molecular Glue Technology
The development of molecular glue degraders represents a transformative advancement in drug discovery, enabling the selective elimination of disease-causing proteins that were previously considered undruggable. This technology has the potential to deliver highly effective, orally available therapies with improved safety profiles, addressing significant unmet needs in oncology.
As KT-200 progresses toward clinical development, the collaboration between Kymera and Gilead highlights the critical role of innovation-driven partnerships in accelerating the delivery of next-generation cancer treatments and improving patient outcomes worldwide.
The licensing of KT-200 marks a pivotal moment in the evolution of targeted protein degradation therapies, combining scientific innovation with strategic collaboration to advance precision oncology solutions. With strong preclinical data and a clear pathway toward clinical development, this program exemplifies how biopharmaceutical partnerships can accelerate drug discovery and expand therapeutic possibilities for patients facing difficult-to-treat cancers.
As the industry continues to explore novel mechanisms of action, KT-200 stands as a promising candidate in the next wave of transformative cancer therapies.
Source: Kymera Therapeutics press release
